Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07214311 · ClinicalTrials.gov registry record · Phase 2

Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty

A Phase 2 study of Prosthetic-joint Infection, sponsored by Peptilogics.

Recruiting
Registry status
Phase 2
Development phase
240
Enrollment target
7
Study locations

NCT07214311 is a Phase 2 study of Prosthetic-joint Infection that is actively recruiting participants, run by Peptilogics. The registered enrollment target is 240 participants, above the 72-participant average among 9 other Prosthetic-joint Infection trials with a reported enrollment target (233% higher). The trial reports 7 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07214311, a Phase 2 study of Prosthetic-joint Infection, is actively recruiting participants, sponsored by Peptilogics.

RECRUITING
Registry status
Phase 2
Development phase
240 participants
Enrollment target
7
Study locations

Study Summary

The goal of this clinical trial is to evaluate whether the investigational drug PLG0206 can help reduce recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR (Debridement, Antibiotics, and Implant Retention) surgical procedure to treat a Prosthetic Joint Infection (PJI). The study will also assess the safety of PLG0206 when used as an irrigation solution during the DAIR procedure. Participants will receive either PLG0206 or a placebo (an inactive substance that looks like the investigational drug), in addition to standard of care treatments. All participants will be monitored for approximately one year following their DAIR procedure.

Conditions Studied

Prosthetic-joint Infection

Interventions

  • DRUG Placebo
  • DRUG PLG0206

Study Locations (7)

Florida

  • Clinical Trial Site - Sarasota
  • Clinical Trial Site - Tamarac

Ohio

  • Clinical Trial Site - Cincinnati
  • Clinical Trial Site - Columbus

Maryland

  • Clinical Trial Site - Baltimore

Massachusetts

  • Clinical Trial Site - Boston

West Virginia

  • Clinical Trial Site - Morgantown

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2026-02-03
Est. Completion 2028-09
Phase Phase 2

Sponsor

Peptilogics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07214311

The ClinicalTrials.gov registry entry for NCT07214311 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 72-participant average among 9 other Prosthetic-joint Infection trials with a reported enrollment target (233% higher). The listed sponsor is Peptilogics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prosthetic-joint Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07214311 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Florida, Ohio, Maryland.

Frequently Asked Questions

What is clinical trial NCT07214311 about?

NCT07214311 is a clinical study titled "Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty". The goal of this clinical trial is to evaluate whether the investigational drug PLG0206 can help reduce recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR (Debridement, Antibiotics, and Implant Retention) surgical procedure to treat a Prosthetic Join...

What is the current status of trial NCT07214311?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2026-02-03. Estimated completion is 2028-09.

What conditions does trial NCT07214311 study?

This clinical trial studies the following conditions: Prosthetic-joint Infection.

What interventions are being tested in trial NCT07214311?

The interventions under investigation include: Placebo (DRUG), PLG0206 (DRUG).

Who is sponsoring clinical trial NCT07214311?

This trial is sponsored by Peptilogics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07214311 being conducted?

This trial has 7 study locations across Florida, Maryland, Massachusetts, Ohio, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prosthetic-joint Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prosthetic-joint Infection

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.